Results 11 to 20 of about 16,733 (229)

In Vitro Evaluation of the Activity of Aztreonam-Avibactam against 341 Recent Clinical Isolates of Anaerobes

Microbiology Spectrum, 2021
Aztreonam-avibactam is under clinical development for multidrug-resistant Gram-negative infections. We evaluated in vitro activity against 341 recent clinical isolates.
David R. Snydman, Laura McDermott
doaj   +3 more sources

Pharmacokinetics of Aztreonam-Avibactam After Single- and Multiple-Dose Administration: A Phase 1, Open-Label Study in Healthy Chinese Participants and Ethnic Comparison with Non-Chinese Participants. [PDF]

Clin Pharmacol Drug Dev
ABSTRACT Combined treatment with aztreonam (an established intravenous antibiotic) and avibactam (a β‐lactamase inhibitor) has the potential to address the unmet need for safe and effective agents to combat infections caused by Gram‐negative bacteria producing metallo β‐lactamases (MBLs).
Wang J, He J, Wu J, Zhang J, Ma Y, Ren X, Wei H, Zhang C, Zhu H, Raber SR, Cong S.   +10 more
europepmc   +2 more sources

Microbiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam–Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against Enterobacterales [PDF]

Infectious Diseases and Therapy
Introduction Aztreonam–avibactam was approved for adults with limited treatment options for multiple infections due to aerobic Gram-negative organisms in the European Union and for complicated intra-abdominal infection in the US, following the phase 3 ...
Susan R. Raber, Rujia Xie, Halley Rogers, Elena Soto, Francis F. Arhin, Gregory G. Stone, Heidi Leister-Tebbe, Joseph W. Chow   +7 more
doaj   +2 more sources

Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017

Journal of Global Antimicrobial Resistance, 2021
Objectives: While aztreonam-avibactam is a potent β-lactam-β-lactamase-inhibitor combination, reduced in vitro activity against some Enterobacterales isolates has been reported. In this study, globally collected clinical isolates of Enterobacterales with
Mark Estabrook, Krystyna M. Kazmierczak, Mark Wise, Francis F. Arhin, Gregory G. Stone, Daniel F. Sahm   +5 more
doaj   +3 more sources

High in vitro activity of aztreonam/avibactam against NDM-producing Enterobacterales with emerging resistance in Escherichia coli in the United States Mid-Atlantic region [PDF]

Microbiology Spectrum
New Delhi metallo-β-lactamase (NDM)-producing Enterobacterales represent a critical antimicrobial resistance threat with limited therapeutic options. Aztreonam/avibactam, which combines the stability of aztreonam against metallo-β-lactamases with the ...
Eetu Eklund, Tyler Maruca, Kate Kruczynski, Heather Critchfield, Robert Murphy, Eric Keller, Benjamin Lee, Ami Patel, Liore Klein, David A. Torpey, Robert A. Myers, Victoria L. Campodónico   +11 more
doaj   +2 more sources

Validation of Aztreonam-Avibactam Susceptibility Testing Using Digitally Dispensed Custom Panels

Journal of Clinical Microbiology, 2020
Aztreonam-avibactam is a combination antimicrobial agent with activity against carbapenemase-producing Enterobacteriaceae (CPE) with metallo-β-lactamases (MβLs). Although aztreonam-avibactam is not yet approved by the U.S.
Eric Ransom, Amelia Bhatnagar, Allison Brown   +2 more
exaly   +4 more sources

Accurate and Sensitive UHPLC–Tandem Mass Spectrometry Sequential Methods for Therapeutic Drug Monitoring of Aztreonam/Avibactam in Human Plasma [PDF]

Pharmaceutics
Background/Objectives: The aztreonam/avibactam combination represents a promising therapeutic option for severe infections caused by multidrug-resistant Gram-negative pathogens, particularly in critically ill patients.
Ilaria Trozzi, Beatrice Giorgi, Riccardo De Paola, Milo Gatti, Federico Pea   +4 more
doaj   +2 more sources

Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE). [PDF]

JAC Antimicrob Resist
Background The Phase 3 ASSEMBLE study investigated aztreonam–avibactam versus best available therapy (BAT) for treatment of complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), hospital-acquired/ventilator-associated ...
Daikos GL, Cisneros JM, Carmeli Y, Wang M, Leong CL, Pontikis K, Anderzhanova A, Florescu S, Kozlov R, Rodriguez-Noriega E, Psichogiou M, Rattanaumpawan P, Streinu-Cercel A, Ramasubramanian V, Arhin FF, Rogers H, Wible M, Leaney J, Jacobson D, Pypstra R, Chow JW.   +20 more
europepmc   +2 more sources

Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-β-lactamase-producing Enterobacterales. [PDF]

Antimicrob Agents Chemother
We evaluated the activity of aztreonam-avibactam and comparators tested against 490 MBL-producing Enterobacterales isolates collected in 27 countries during 2019–2022. The most common MBL was NDM-1, which was detected among 307 isolates.
Castanheira M, Kimbrough JH, Morgan GM, Karr M, Sader HS.   +4 more
europepmc   +2 more sources

Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales. [PDF]

J Antimicrob Chemother
Background Aztreonam/avibactam is a novel β-lactam/β-lactamase inhibitor (BL/BLI) combination active against carbapenem-resistant Enterobacterales (CRE), including MBL-producing isolates.
Baltas I, Tsakri D, Vourli S, Solanki H, Murrell E, Kiousi E, Tsakris Z, Kuczmar G, Smyrni N, Skiadas I, Grammelis V, Hatcher J, Menegas D, Tsakris A, Vrioni G, Grandjean L.   +15 more
europepmc   +2 more sources